SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law

Non-Compliance Means Nasdaq De-Listing In 2024

 
• By Mandy Jackson
  
Stock market chart with US and China flag overlays
US-listed Chinese companies face accounting firm scrutiny • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Compliance

More from Pink Sheet